Portal de Periódicos da CAPES

Hypertrophic Cardiomyopathy, Athlete’s Heart, or Both

2015; Lippincott Williams & Wilkins; Volume: 8; Issue: 7 Linguagem: Inglês

10.1161/circimaging.115.003312

1942-0080

Kalie Kebed, J. Martijn Bos, Nandan S. Anavekar, Sharon L. Mulvagh, Michael J. Ackerman, Steve R. Ommen,

Congenital Heart Disease Studies

HomeCirculation: Cardiovascular ImagingVol. 8, No. 7Hypertrophic Cardiomyopathy, Athlete's Heart, or Both Free AccessResearch ArticlePDF/EPUBAboutView PDFView EPUBSections ToolsAdd to favoritesDownload citationsTrack citationsPermissionsDownload Articles + Supplements ShareShare onFacebookTwitterLinked InMendeleyReddit Jump toSupplemental MaterialFree AccessResearch ArticlePDF/EPUBHypertrophic Cardiomyopathy, Athlete's Heart, or BothA Case of Hypertrophic Cardiomyopathy Regression Kalie Y. Kebed, MD, J. Martijn Bos, MD, PhD, Nandan S. Anavekar, MBBCh, Sharon L. Mulvagh, MD, Michael J. Ackerman, MD, PhD and Steve R. Ommen, MD Kalie Y. KebedKalie Y. Kebed From the Department of Medicine, Division of Internal Medicine (K.Y.K.), Department of Pediatric and Adolescent Medicine, Division of Pediatric Cardiology (J.M.B.), Department of Medicine, Division of Cardiovascular Diseases (N.S.A., S.L.M., S.R.O.), Department of Pediatric and Adolescent Medicine, Division of Pediatric Cardiology (M.J.A.), and Department of Medicine, Division of Cardiovascular Diseases (M.J.A.), Mayo Clinic, Rochester, MN. , J. Martijn BosJ. Martijn Bos From the Department of Medicine, Division of Internal Medicine (K.Y.K.), Department of Pediatric and Adolescent Medicine, Division of Pediatric Cardiology (J.M.B.), Department of Medicine, Division of Cardiovascular Diseases (N.S.A., S.L.M., S.R.O.), Department of Pediatric and Adolescent Medicine, Division of Pediatric Cardiology (M.J.A.), and Department of Medicine, Division of Cardiovascular Diseases (M.J.A.), Mayo Clinic, Rochester, MN. , Nandan S. AnavekarNandan S. Anavekar From the Department of Medicine, Division of Internal Medicine (K.Y.K.), Department of Pediatric and Adolescent Medicine, Division of Pediatric Cardiology (J.M.B.), Department of Medicine, Division of Cardiovascular Diseases (N.S.A., S.L.M., S.R.O.), Department of Pediatric and Adolescent Medicine, Division of Pediatric Cardiology (M.J.A.), and Department of Medicine, Division of Cardiovascular Diseases (M.J.A.), Mayo Clinic, Rochester, MN. , Sharon L. MulvaghSharon L. Mulvagh From the Department of Medicine, Division of Internal Medicine (K.Y.K.), Department of Pediatric and Adolescent Medicine, Division of Pediatric Cardiology (J.M.B.), Department of Medicine, Division of Cardiovascular Diseases (N.S.A., S.L.M., S.R.O.), Department of Pediatric and Adolescent Medicine, Division of Pediatric Cardiology (M.J.A.), and Department of Medicine, Division of Cardiovascular Diseases (M.J.A.), Mayo Clinic, Rochester, MN. , Michael J. AckermanMichael J. Ackerman From the Department of Medicine, Division of Internal Medicine (K.Y.K.), Department of Pediatric and Adolescent Medicine, Division of Pediatric Cardiology (J.M.B.), Department of Medicine, Division of Cardiovascular Diseases (N.S.A., S.L.M., S.R.O.), Department of Pediatric and Adolescent Medicine, Division of Pediatric Cardiology (M.J.A.), and Department of Medicine, Division of Cardiovascular Diseases (M.J.A.), Mayo Clinic, Rochester, MN. and Steve R. OmmenSteve R. Ommen From the Department of Medicine, Division of Internal Medicine (K.Y.K.), Department of Pediatric and Adolescent Medicine, Division of Pediatric Cardiology (J.M.B.), Department of Medicine, Division of Cardiovascular Diseases (N.S.A., S.L.M., S.R.O.), Department of Pediatric and Adolescent Medicine, Division of Pediatric Cardiology (M.J.A.), and Department of Medicine, Division of Cardiovascular Diseases (M.J.A.), Mayo Clinic, Rochester, MN. Originally published10 Jul 2015https://doi.org/10.1161/CIRCIMAGING.115.003312Circulation: Cardiovascular Imaging. 2015;8:e003312Hypertrophic cardiomyopathy (HCM) is a genetic cardiovascular disease characterized by a hypertrophied, nondilated left ventricle (LV) in the absence of other causes. HCM is relatively common and is one of the most common causes of sudden death in athletes.1 HCM is genotypically and phenotypically heterogenous.2,3 The differential diagnosis for HCM includes physiological remodeling seen in athlete's heart.4 Distinguishing HCM from athlete's heart is of critical importance. Characteristics favoring HCM and athlete's heart are listed in the Table.Table. Characteristics Favoring HCM and Athlete's HeartFavors HCMFavors Athlete's HeartAsymmetrical hypertrophyHomogenous hypertrophy with maximal thickness of 15 mmDiastolic dysfunctionEllipsoid LV shapeLate gadolinium enhancement on cardiac MRIRegression with deconditioningHCM indicates hypertrophic cardiomyopathy; and LV, left ventricular.An 18-year-old man was referred for evaluation after a markedly abnormal ECG (Figure 1A) was discovered at a professional hockey scouting event. He was otherwise healthy and asymptomatic. He had no family history of cardiomyopathies or sudden unexplained death. A contrast enhanced transthoracic echocardiogram showed apical HCM with a maximal LV wall thickness of 24 mm and spade-like appearance (Movie I in the Data Supplement). LV chamber size and systolic function were normal without dynamic obstruction. Diastolic function assessment showed indeterminate diastolic function grade. On cardiac MRI, the apex and anterior septum measured 25 and 13 mm, respectively (Figure 2A; Movie II in the Data Supplement). First pass perfusion was normal, but postcontrast images demonstrated patchy areas of late gadolinium enhancement suggestive of fibrosis (Figure 3A). Exercise ECG and 24-hour Holter monitor showed no ventricular arrhythmias. On genetic testing, a de novo HCM-associated mutation in MYH7-encoded β myosin heavy chain gene at position 530 (p. Ile530Val) was identified. The patient's parents and 2 siblings, all phenotype negative for HCM, tested negative for the mutation.Download figureDownload PowerPointFigure 1. A, Initial ECG demonstrating left ventricular hypertrophy voltage criteria, ST depression, and deeply inverted T waves consistent with apical hypertrophic cardiomyopathy. B, Follow-up ECG (14 months) with less prominent T wave inversions.Download figureDownload PowerPointFigure 2. A, Initial cardiac MRI steady-state free precession sequence in a 4-chamber view demonstrating apical hypertrophy (June 2008). B, Follow-up cardiac MRI (August 2009) demonstrating regression of apical hypertrophy.Download figureDownload PowerPointFigure 3. A, Postcontrast delayed enhancement sequence represented in a long axis view demonstrating the presence of apical hypertrophy and abnormal patchy apical myocardial delayed enhancement (June 2008). B, Follow-up cardiac MRI demonstrating regression of apical hypertrophy but persistence of abnormal myocardial delayed enhancement (August 2009). LGE indicates late gadolinium enhancement.The patient was counseled on the natural history of HCM and the risk of sudden death with competitive athletics. None of the standard sudden death risk markers were present at the initial evaluation, and therefore there was no indication for an implantable cardioverter defibrillator. The patient discontinued his rigorous athletic training, but continued to lead a relatively active lifestyle.He was seen for follow-up 14 months after the initial diagnosis. Repeat cardiac MRI showed complete resolution of the LV hypertrophy with maximal wall thickness of 10 mm at the apex (Figure 2B; Movie III in the Data Supplement). However, the patchy areas of late gadolinium enhancement were unchanged (Figure 3B). On repeat noncontrast echocardiogram, maximum thickness was 12 mm at the apex (Movie IV in the Data Supplement). The ST depression and deeply inverted T waves were less prominent on his repeat ECG (Figure 1B). Because of the regression of hypertrophy after detraining and negative genetic testing in family members, genetic testing was repeated to exclude the possibility of a false-positive result, but he was again found to be genotype positive.He continued to be asymptomatic until 16 months after the diagnosis when he developed presyncope and tachy-palpitations. An event recorder demonstrated episodes of supraventricular tachycardia and nonsustained ventricular tachycardia. Given his symptoms, documented nonsustained ventricular tachycardia, and late gadolinium enhancement on cardiac MRI, an implantable cardioverter defibrillator was implanted. Since the implantable cardioverter defibrillator placement, now >5 years ago, the patient has done well with no appropriate implantable cardioverter defibrillator discharges. On his most recent echocardiogram (6 years and 2 months since diagnosis), maximum thickness remained 12 mm at the apex.These images demonstrate a novel case of LV hypertrophy regression after detraining in a patient with clinical HCM and an HCM-associated mutation. There are limited data supporting regression of LV hypertrophy with pharmacotherapy and surgical relief of outflow tract obstruction, but to our knowledge none on regression after detraining. At initial diagnosis, the extreme ECG changes, marked asymmetrical hypertrophy, late gadolinium enhancement, and genetic mutation were all consistent with an underlying pathological process (ie, sarcomeric HCM) rather than physiological adaptation. However, it is possible the patient has both athletic adaptation to intense training which has currently regressed and HCM. Alternatively, this case may challenge the existing dogma that regression is only seen in physiological remodeling such as athlete's heart and that HCM phenotypic conversion is not altered by exogenous loads on the heart. Overall, it is of clinical importance to distinguish HCM and athlete's heart because of the differing recommendations and prognosis. The potential lifestyle restrictions for HCM have not only physical ramifications but also psychological and financial, as in this patient who was a professional athlete prospect.DisclosuresNone.FootnotesThe Data Supplement is available at http://circimaging.ahajournals.org/lookup/suppl/doi:10.1161/CIRCIMAGING.115.003312/-/DC1.Correspondence to Kalie Y. Kebed, MD, Mayo Clinic, 200 1st St SW, Rochester MN 55905. E-mail [email protected]References1. Maron BJ, Ommen SR, Semsarian C, Spirito P, Olivotto I, Maron MS.Hypertrophic cardiomyopathy: present and future, with translation into contemporary cardiovascular medicine.J Am Coll Cardiol. 2014; 64:83–99. doi: 10.1016/j.jacc.2014.05.003.CrossrefMedlineGoogle Scholar2. Binder J, Ommen SR, Gersh BJ, Van Driest SL, Tajik AJ, Nishimura RA, Ackerman MJ.Echocardiography-guided genetic testing in hypertrophic cardiomyopathy: septal morphological features predict the presence of myofilament mutations.Mayo Clin Proc. 2006; 81:459–467. doi: 10.4065/81.4.459.CrossrefMedlineGoogle Scholar3. Bos JM, Towbin JA, Ackerman MJ.Diagnostic, prognostic, and therapeutic implications of genetic testing for hypertrophic cardiomyopathy.J Am Coll Cardiol. 2009; 54:201–211. doi: 10.1016/j.jacc.2009.02.075.CrossrefMedlineGoogle Scholar4. Pelliccia A, Maron MS, Maron BJ.Assessment of left ventricular hypertrophy in a trained athlete: differential diagnosis of physiologic athlete's heart from pathologic hypertrophy.Prog Cardiovasc Dis. 2012; 54:387–396. doi: 10.1016/j.pcad.2012.01.003.CrossrefMedlineGoogle Scholar Previous Back to top Next FiguresReferencesRelatedDetailsCited By Colan S and Margossian R (2018) Hypertrophic Cardiomyopathy Heart Failure in the Child and Young Adult, 10.1016/B978-0-12-802393-8.00019-3, (239-267), . Geske J, Ommen S and Gersh B (2018) Hypertrophic Cardiomyopathy, JACC: Heart Failure, 10.1016/j.jchf.2018.02.010, 6:5, (364-375), Online publication date: 1-May-2018. Barretta F, Mirra B, Monda E, Caiazza M, Lombardo B, Tinto N, Scudiero O, Frisso G and Mazzaccara C (2020) The Hidden Fragility in the Heart of the Athletes: A Review of Genetic Biomarkers, International Journal of Molecular Sciences, 10.3390/ijms21186682, 21:18, (6682) July 2015Vol 8, Issue 7 Advertisement Article InformationMetrics © 2015 American Heart Association, Inc.https://doi.org/10.1161/CIRCIMAGING.115.003312PMID: 26162782 Manuscript receivedFebruary 24, 2015Manuscript acceptedJune 15, 2015Originally publishedJuly 10, 2015 Keywordsdefibrillator, implantabletachycardia, supraventricularcardiomyopathy, hypertrophicdeath, suddenathletesPDF download Advertisement SubjectsCardiomyopathyComputerized Tomography (CT)Echocardiography